Lesinurad Intermediate CAS 1533519-85-5 Purity >99.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of Methyl 2-[[4-(4-Cyclopropylnaphthalen-1-yl)-4H-1,2,4-Triazol-3-yl]thio]acetate (CAS: 1533519-85-5) with high quality, intermediate of Lesinurad (CAS: 878672-00-5). Ruifu Chemical can provide worldwide delivery, competitive price, excellent service, small and bulk quantities available. Purchase Lesinurad Intermediates, Please contact: alvin@ruifuchem.com
| Chemical Name | Methyl 2-[[4-(4-Cyclopropylnaphthalen-1-yl)-4H-1,2,4-Triazol-3-yl]thio]acetate |
| Synonyms | Lesinurad INT4; Lesinurad Impurity 11; Methyl {[4-(4-Cyclopropyl-1-Naphthyl)-4H-1,2,4-Triazol-3-yl]sulfanyl}acetate |
| Stock Status | In Stock, Commercial Production |
| CAS Number | 1533519-85-5 |
| Molecular Formula | C18H17N3O2S |
| Molecular Weight | 339.41 g/mol |
| Boiling Point | 546.4±60.0℃ |
| Density | 1.38±0.10 g/cm3 |
| COA & MSDS | Available |
| Origin | Shanghai, China |
| Category | Intermediate of Lesinurad (CAS: 878672-00-5) |
| Brand | Ruifu Chemical |
| Items | Inspection Standards | Results |
| Appearance | Off-White Powder | Off-White Powder |
| Purity / Analysis Method | >99.0% (HPLC) | 99.6% |
| The Largest Single impurity | <0.50% | 0.2% |
| Total Impurities | <1.00% | 0.4% |
| Water by Karl Fischer | <0.50% | 0.1% |
| Loss on Drying | <0.50% | 0.1% |
| Residue on Ignition | <0.20% | 0.1% |
| Infrared Spectrum | Conforms to Structure | Complies |
| 1H NMR Spectrum | Conforms to Structure | Complies |
| Conclusion | The product has been tested and complies with the given specifications | |
Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry (2~8℃) and well-ventilated warehouse away from incompatible substances. Protect from light and moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.
How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.
Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.
Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.
Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.
Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.
Factory Audit? Factory audit welcome. Please make an appointment in advance.
MOQ? No MOQ. Small order is acceptable.
Delivery Time? If within stock, three days delivery guaranteed.
Transportation? By Express (FedEx, DHL), by Air, by Sea.
Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.
Custom Synthesis? Can provide custom synthesis services to best fit your research needs.
Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
Methyl 2-[[4-(4-Cyclopropylnaphthalen-1-yl)-4H-1,2,4-Triazol-3-yl]thio]acetate (CAS: 1533519-85-5) is used as an intermediate of Lesinurad (CAS: 878672-00-5). Approved by the FDA late in 2015, lesinurad is an urate anion exchange transporter 1 (URAT1) inhibitor for use in the treatment of gout. Ardea Biosciences, which is a subsidiary of AstraZeneca, developed lesinurad to be used in a combination therapy with xanthine oxidase inhibitors for the treatment of hyperuricaemia associated with gout. The approval process is ongoing in several other countries across the globe, with the EMA Committee for Medicinal Products for Human Use giving lesinurad a positive opinion for use as an adjunctive therapy in combination with xanthine oxidase inhibitors to treat hyperuricaemia.
